Last edition
News about
Innovent's PECONDLE Becomes China's First Approved IL-23p19 Antibody
Innovent has received NMPA approval for PECONDLE (picankibart injection), marking China’s first IL-23p19 monoclonal antibody to be cleared for treating moderate-to-severe plaque psoriasis in adults eligible for systemic therapy.
Aptar Expands Latin American Footprint with Acquisition of Sommaplast
AptarGroup, a global leader in drug and consumer product dosing, dispensing and protection technologies, has acquired Sommaplast, a Brazil-based specialist in oral dosing pharma packaging solutions. Sommaplast’s portfolio includes closures, droppers, dispensers and dosing cups.
SUDPACK Breaks Ground on Major Expansion to Boost PharmaGuard Production
SÜDPACK has officially begun work on a major expansion at its logistics centre in Erolzheim, Germany, as part of a strategic move to scale up production of its sustainable pharmaceutical packaging solutions.
Lilly Lowers Zepbound's Single-dose Vials' Cost
Lilly has reduced the price of its Zepbound (tirzepatide) single-dose vials, reinforcing its commitment to improving affordability and expanding access for people living with obesity.
Verida: Philips unveils first AI-driven detector-based spectral CT
The new platform integrates AI across the entire imaging chain—from acquisition to reconstruction—to reduce system noise, enhance image clarity, and significantly accelerate clinical workflows.
Jubilant Pharmova Appoints Daniel J. O'Connor as CEO of Jubilant Therapeutics
Jubilant Pharmova has announced the appointment of Daniel J. O’Connor as CEO of its proprietary novel drugs business, Jubilant Therapeutics Inc.
Zaynich milestone: First Indian-developed NCE accepted by US FDA
Wockhardt Ltd. today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for its novel, first-in-class antibiotic Zaynich.
Biocon Biologics Reaches Settlement with Amgen, Secures Market Entry Date for Denosumab Biosimilars
Biocon Biologics will introduce both its Denosumab biosimilars — Vevzuo and Evfraxy — in Europe beginning December 2, 2025. Other terms of the settlement with Amgen remain confidential.
NPPA Fixes Retail Prices for 11 Drug Formulations Under DPCO 2013
The National Pharmaceutical Pricing Authority (NPPA) has issued a fresh notification fixing retail prices for multiple essential drug formulations—including antihypertensives, antibiotics, antidiabetics, and paediatric syrups—under the Drugs (Prices Control) Order, 2013. The revised prices apply to approved manufacturers and exclude GST.
Generate:Biomedicines to Begin Phase 3 Trials of AI-Engineered Asthma Antibody GB-0895
Generate:Biomedicines is set to begin its first global Phase 3 trials for GB-0895, an AI-engineered long-acting anti-TSLP antibody for patients with severe, uncontrolled asthma. The SOLAIRIA-1 and SOLAIRIA-2 studies will evaluate the therapy in about 1,600 patients, marking a key milestone for programmable biology in respiratory care.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy